No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ALLK240621P2500
- 1.35
- +0.14+11.57%
15min DelayClose Jun 18 15:59 ET
1.35High1.35Low
1.35Open1.21Pre Close20 Volume25 Open Interest2.50Strike Price2.70KTurnover687.18%IV-2.68%PremiumJun 21, 2024Expiry Date1.38Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9065Delta0.2934Gamma0.80Leverage Ratio-0.0175Theta-0.0001Rho-0.73Eff Leverage0.0001Vega
Intraday
- 5D
- Daily
News
Analysts Offer Insights on Healthcare Companies: Clene (CLNN) and Allakos (ALLK)
Express News | Allakos Says First Patient Has Been Dosed In Phase 1 Trial Of AK006 In Chronic Spontaneous Urticaria
Express News | Allakos Inc - Top-Line Phase 1 Csu Results Expected at Year End 2024
Express News | Allakos Announces First Patient Dosed in Phase 1 Trial of Ak006 in Chronic Spontaneous Urticaria
Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions
Comments
$Allakos(ALLK.US$ Allakos Announces First Patient Dosed in Phase 1 Trial of Ak006 in Chronic Spontaneous Urticaria! Top-Line Phase 1 Csu Results Expected at Year End 2024
1
$Allakos(ALLK.US$ mark my words buyout rumors or news in 2-3 months
$Allakos(ALLK.US$ Allakos | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.8%)
SEC announcement
·
01/29 17:30
SEC announcement
·
01/29 17:30
1
Read more